Sign inCreate account

Report workspace tools

NCT05016349UNKNOWNanonymous

Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer

Sponsor

Source record

Mahmoud Ramadan mohamed Elkazzaz

Phase

Source record

Phase II

Modality

AI-normalized

small molecule

Target

AI-normalized

Breast Cancer

Indication / condition

AI-normalized

Breast Cancer Female

Intervention

Source record

All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, 9 cis retinoic acid, Tamoxifen, Standard therapy

Source & freshness

Source record

NCT ID

NCT05016349

Original source

ClinicalTrials.gov

Source last updated

Aug 23, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05016349

Title

Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer

Sponsor

Mahmoud Ramadan mohamed Elkazzaz

Status

UNKNOWN

Phase

Phase II

Condition raw

Breast Cancer Female

Condition normalized

Breast Cancer Female

Modality raw

Breast Cancer Female

Modality normalized

small molecule

Target raw

Breast Cancer

Target normalized

Breast Cancer

Interventions

All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, 9 cis retinoic acid, Tamoxifen, Standard therapy

Public preview

Source record

This clinical trial investigates a novel quadrate combination therapy involving Mifepristone, Tamoxifen, Retinoic Acid, and Cannabidiol for treating early breast cancer. The study aims to evaluate the anti-tumor activity of this combination and its effects on CK5-expressing cells, addressing therapy resistance in ERα-positive breast cancer.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05016349

Status

UNKNOWN

Phase

Phase II

Sponsor

Mahmoud Ramadan mohamed Elkazzaz

Executive brief

Investment-Ready Snapshot

This clinical trial investigates a novel quadrate combination therapy involving Mifepristone, Tamoxifen, Retinoic Acid, and Cannabidiol for treating early breast cancer. The study aims to evaluate the anti-tumor activity of this combination and its effects on CK5-expressing cells, addressing therapy resistance in ERα-positive breast cancer.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 23, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05016349

Indication

Breast Cancer Female

Modality

small molecule

Target

Breast Cancer

Intervention

All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, 9 cis retinoic acid, Tamoxifen, Standard therapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.